As­traZeneca re­ports Phase 3 suc­cess for rare dis­ease drug at heart of Amolyt deal

As­traZeneca’s $1.05 bil­lion bet on French biotech Amolyt Phar­ma seems to be pay­ing off.

On Mon­day, the UK drug­mak­er re­port­ed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.